The U.S. FDA moved toward faster decision-making by launching a pilot program to collect and review clinical trial data in real time. The agency said it will give reviewers access to information as it is generated, with early participation from AstraZeneca and Amgen-backed studies. FDA officials framed the approach as a way to reduce reporting lag between trial completion and regulator review, while still keeping safety monitoring and submissions structured for downstream decisions. The pilot will also solicit public input on expanding the model to additional sponsors using AI for safety monitoring, dosing selection, signal detection, and recruitment. Separate from the pilot announcement, FDA also prepared briefing materials tied to oncology advisory meetings, underscoring that real-time data access is becoming a practical lever for regulators as they manage review timelines. For biotech teams, the message is straightforward: trial data workflows, governance, and documentation practices may need to be rebuilt to support continuous regulator visibility rather than point-in-time submission snapshots.